Inhibrx Biosciences Inc.
NASDAQTotal Valuation
Inhibrx Biosciences Inc. carries a market capitalization of 1.40B, placing it among publicly traded companies globally. Its enterprise value stands at 1.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.40B |
| Enterprise Value | 1.44B |
Share Statistics
Inhibrx Biosciences Inc. currently has 14.71M shares outstanding.
| Shares Outstanding | 14.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -26.31 |
| P/TBV Ratio | -26.31 |
| P/FCF Ratio | -11.18 |
| P/OCF Ratio | -11.18 |
Financial Position
Inhibrx Biosciences Inc. maintains a current ratio of 5.07, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -342.84, indicating conservative leverage, while an interest coverage ratio of -8.07 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.07 |
| Quick Ratio | 4.76 |
| Debt / Equity | -342.84 |
| Debt / EBITDA | -1.45 |
| Interest Coverage | -8.07 |
Financial Efficiency
| Return on Equity (ROE) | -341.92 |
| Return on Assets (ROA) | -75.44 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 3,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Inhibrx Biosciences Inc.'s stock has gained approximately 148.63946% over the past 52 weeks. The 50-day moving average sits at 103.73, while the 200-day moving average is 91.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | 148.63946% |
| 50-Day Moving Average | 103.73 |
| 200-Day Moving Average | 91.59 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -125.60M, while operating income came in at -127.81M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -127.81M |
| Pretax Income | -138.18M |
| Net Income | -138.18M |
| EBITDA | -125.60M |
| EBIT | -127.81M |
| Earnings Per Share (EPS) | -8.88 |
Balance Sheet
Inhibrx Biosciences Inc. holds 133.34M in cash and equivalents against 181.63M in total debt, resulting in a net debt position of 42.94M. Total book value stands at -52.98M, with working capital of 114.15M providing operational flexibility.
| Cash & Cash Equivalents | 133.34M |
| Total Debt | 181.63M |
| Net Debt | 42.94M |
| Equity (Book Value) | -52.98M |
| Book Value Per Share | -3.60 |
| Working Capital | 114.15M |
Cash Flow
Inhibrx Biosciences Inc. produced -131.89M in operating cash flow over the past twelve months. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -131.90M - equivalent to -8.47 per share.
| Operating Cash Flow | -131.89M |
| Capital Expenditures | -10,000.00 |
| Free Cash Flow | -131.90M |
| FCF Per Share | -8.47 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.65 |
| FCF Yield | -8.94 |
Scores
Inhibrx Biosciences Inc. posts an Altman Z-Score of -0.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.68 |